To The Moon

When people talk about the next trillion-dollar tech giant, $Oracle(ORCL)$ isn’t usually the first name that comes to mind. Yet, this enterprise stalwart is quietly assembling the pieces for a major leap forward. With a current valuation of around $403 billion, Oracle’s aggressive expansion into AI and cloud computing could soon make it a heavyweight contender. Let’s break down why this database veteran may be one of the most underrated growth stories in tech today. AI Infrastructure: Oracle’s Not Here to Out-Amazon Amazon Many investors wrongly assume that Oracle is trying to go head-to-head with AWS or Azure in the cloud wars. That’s not the play here. Instead, Oracle is strategically positioning itself as the go-to provider for high-performance

In 2025, sustainable technology investing has shifted from a niche interest to a mainstream strategy, with the market projected to grow from $26.85 billion in 2024 to $121.05 billion by 2032 (CAGR of 20.7%). This surge is fueled by advances in renewable energy, supportive government policies, and rising consumer demand for eco-friendly solutions. However, challenges remain. The U.S. administration’s reduced support for green projects has contributed to a decline in clean energy stocks, with the S&P Global Clean Energy Transition index dropping 0.16% over the past year. Despite this, global sustainability efforts persist, and investors focused on long-term trends like nature-positive strategies and the circular economy are well-positioned for future growth.

Loss PNL T_T OMG Broooooo

$GRANITESHARES 2X LONG BABA DAILY ETF(BABX)$ $Alibaba(BABA)$ $3X BABA(BAB3.UK)$🇨🇳🔥🌐⚒️ Alibaba’s Algorithmic Dominion Expands, $BABX as My Conduit into a Predictive Matrix ⚒️🌐 Tiger Traders, on 18 March 2025 (NZ time), I’ve anchored into $BABX, the 2x Long BABA ETF, at $34.91, now up 0.76%, as Alibaba ($BABA) commands $147.78, a 66% YTD titan outmuscling OKTA, TEM, SMCI, and PDD. This isn’t a transient blip, it’s a coded reconfiguration of market geometry, beckoning a trader’s precision scalpel. 📈 The Structural Lattice $BABA has obliterated 52 week highs, propelled by StockConnect’s record inflows and China’s consumption renaissance. Its new AI model, rivallin

$ulta beauty(ULTA)$ Earning Overview Ulta reported $8.46 EPS, beating expectations by $1.31—a massive beat. Revenue also topped estimates by $10 million, though year-over-year revenue growth has slowed. Comparable sales increased 1.5%, and while the company posted a double beat for the quarter, its full-year guidance slightly missed expectations. ​Ulta Beauty reported its fourth-quarter fiscal 2024 earnings on March 13, 2025, delivering results that exceeded market expectations. The company's net sales for the quarter were $3.49 billion, a slight decrease of 1.9% from the previous year's $3.56 billion. This decline was primarily due to an extra week of sales in the prior year's quarter, which contributed approximately $181.9 million. When adjustin

$NVIDIA(NVDA)$ $Tradr 1.5X Short NVDA Daily ETF(NVDS)$ $Direxion Daily NVDA Bear 1X Shares(NVDD)$ 🚨🔥💥 $NVDA: Triple Top Showdown, Will It CRASH or SOAR? 💥🔥🚨 Hey, fearless traders! Nvidia is staging an epic battle on the charts, and we’ve got front row seats! The $NVDA chart is screaming with a classic “Triple Top” rejection between $122.74 and $123.70 (with a peak at $122.37), a beastly resistance that’s got bulls sweating and bears roaring! Is this the setup for a savage drop, or can the bulls stage a heroic breakout? Let’s dissect this like market ninjas! 🥋📈 📉 Key Battlegrounds to Watch Like a Hawk:    •   Red Fortress (Supply Zone

$Hims & Hers Health Inc.(HIMS)$ Hims & Hers, the rapidly growing telehealth company, has experienced an extraordinary surge over the past few months. In my previous articles on Hims, particularly The Messy Reality of Telehealth, I discussed the disconnect between the company's valuation and its intrinsic worth, arguing that Hims stock was significantly undervalued at the time. Around four months ago, Hims was trading at $23 per share. Fast forward to today, and the stock has not only surpassed my base case price target of $45 but also exceeded my bullish target of $62. However, in the past couple of weeks, Hims stock has pulled back sharply, dropping nearly 50% from its peak of $70 to approximately $33 per share. In this article, I'll anal

$Trade Desk Inc.(TTD)$ Stock Performance and Recent Decline Since I first invested in The Trade Desk, its stock has risen over 10 times, but the journey has been anything but smooth. As you can see over the past three years, it’s been quite a roller coaster—actually, the stock is down over that period. If you zoom in more recently, you'll notice that year-to-date, the stock has lost more than 50% of its value. So, does this mean The Trade Desk is suddenly on the verge of going out of business, or what’s going on with the company that could cause such a sharp decline in value? Typically, a loss of this magnitude in such a short period raises some red flags. Let’s dive in and figure out what’s happening with The Trade Desk. My Experience with The Tra

$Walgreens Boots Alliance(WBA)$ Walgreens Announcement and Investor Lessons Walgreens announced today that it will go private in a deal worth around $10 billion with Sycamore Partners. I wanted to discuss some lessons investors can take away from this, as well as why I personally don't invest in turnaround stocks. This example really highlights why avoiding certain investment strategies can save you from making costly mistakes. My Investing Journey and the Rise of Dividend Growth Investing I first started writing about investing nearly 10 years ago, back in the third quarter of 2015. At that time, Seeking Alpha was a hotspot for dividend growth investors (and still is), but this was especially true before AI and other trends took over. Because bond

$Lucid Group Inc(LCID)$ Lucid, the electric vehicle company, has seen its shares drop by 28% so far in 2025. If you watched my video at the start of the year, I advised against buying Lucid stock in 2025. But now that it’s already down 28%, does that make it a good buying opportunity? I’ll answer that in this video by evaluating the company’s recent performance, its prospects with the Lucid Gravity SUV that just launched, its cash flow, and its valuation to see if it’s time to invest in Lucid stock. From a consumer standpoint, I’m a fan of Lucid. It’s my favorite electric vehicle because of its stunning designs. When I see a Lucid on the road, it looks beautiful—by far my favorite electric car in terms of aesthetics. However, as much as I admire t

On early Mon, 17 Mar 2025 morning (4am US time), US stock futures are looking grim again, coming off Friday’s mini-recovery rally. (see below) US market is going to start the week, marginally lower than last week’s closing. While there is no clear indication that US market will continue to trend lower thereafter. Neither could we foretell that its course may turnaround and rises instead, later in the day. It is a wait-and-see “game”. What is certain ? One of Wall Street preoccupations this week will be, US’s Fed FOMC meeting Mar 18-19. Traders will be dying to know: Central bank’s decision on interest rates. Fed chair Powell’s thoughts on the path forward. Hear him on his thoughts on overall health of US economy that many are certain has been wrecked by the Trump administration and preside

$XPeng Inc.(XPEV)$   Get ready for report tomorrow!! 

$Millicom International Cellular S.A.(TIGO)$   TP at 33

$Novo-Nordisk A/S(NVO)$ NVO's Shocking Decline In my previous analysis on NVO stock, I provided insights into its performance. Today, I decided to offer another update, especially now that the stock has dropped 42% over the past year. It’s absolutely shocking for a company like NVO—one of the best-performing stocks of all time, up 58,000% historically. Yet, it’s now plunging, down nearly 50% from its all-time high. Key Focus of This Update In this update, I'll discuss NVO's recent performance, why the stock is declining, and whether I believe it's presenting a generational buying opportunity at $76 per share—or if it remains overvalued and we should wait for a lower price. My View on Pharmaceutical Stocks Personally, I’m not a huge fan of holding p

Why Hims is on Solid Legal Ground to Continue Selling GLP-1s Even After the Shortage is Over Morgan Stanley analyst Craig Hettenbach just dropped some exciting news for investors in mail-order pharmaceuticals!   According to third-party data, downloads of the Hims & Hers apps skyrocketed 47% year-over-year in February—a massive surge in interest.  On Apple's App Store, Hims & Hers offers two distinct apps: Hims, focused on hair loss and sexual health, and Hers, catering to hair care and mental health. Morgan Stanley's research reveals that the Hers app dominated February's downloads, signaling a wave of new female customers.   What’s behind the spike? A certain high-profile sporting event likely played a role, with targeted ads driving attention to weight-l

$Medical Properties(MPW)$ MPW Stock Update: A Wild Ride MPW stock has been on an absolute tear—up 46% while the broader market is declining. Last year, when the market was rising, MPW was down 40-50%. It’s been a rollercoaster, so I’m doing an update to share my thoughts on whether the stock is approaching overvalued territory or if it’s still a solid opportunity. I’ll also break down the key factors driving this surge. I know some of you have commented about my stock picks, saying you lost money on MPW. As I’ve mentioned before, this stock moves inversely with the 10-year Treasury yield—it has a negative 80% correlation. When interest rates go down, MPW goes up. Why? Because MPW is a dividend stock, and as yields drop, its dividend becomes more at

$S&P 500(.SPX)$ $NASDAQ(.IXIC)$ The 1970s Inflation Crisis and Market Collapse In the 1970s, the U.S. experienced three major inflationary waves, with inflation soaring as high as 15%. Each wave triggered significant stock market declines, with U.S. equities falling by over 20% each time. Fast forward to today, and inflation is once again a growing concern. The recent surge in inflation, the highest since the 1970s, led to a 25% drop in stocks in 2022. Now, with the Trump administration's proposed policies, some economists warn that this could be the beginning of another prolonged inflationary cycle, much like the one seen in the 1970s. IMF Warnings on Inflationary Risks The International Monetary Fu

This week's market focus will be on the Federal Reserve's interest rate decision and the February retail sales data, which reflects economic strength. Looking back at last week's U.S. stock market, the $Dow Jones(.DJI)$ fell by over 1,000 points, while the $S&P 500(.SPX)$ and $NASDAQ(.IXIC)$ each declined by more than 2%. 1. The three major indices hit six-month lows. Compared to this year's peak, the $S&P 500(.SPX)$ has dropped by more than 10%, entering a correction zone.The market generally expects that the Fed will maintain the benchmark interest rate unchanged this time and is also focused on the economic f

$Adobe(ADBE)$ The markets have opened with highly mixed results across various sectors. However, one standout movement is Adobe, which is down nearly 12%, aligning with the broader decline in the technology software industry. Looking at the past month, the market has been dominated by red, with many companies experiencing double-digit losses—Adobe included, which has dropped an additional 5%. Improved Market Sentiment On a more positive note, market sentiment is slightly improving. Just a few days ago, fear levels were extreme at 13, but they have now risen to 22. The hope is that this trend continues, moving away from extreme fear into a more stable range. Adobe's Earnings Report: A Closer Look Today, Adobe is in the spotlight following its lates

As healthcare continues to evolve rapidly, pharmaceutical stocks are at the forefront of innovation in drug development and personalized medicine. In 2025, companies in this sector are leveraging breakthroughs in genomics, immunotherapy, and digital health to deliver cutting-edge treatments. This post explores the fundamentals of pharmaceutical stocks, key drivers behind their growth, diverse applications, investment opportunities and risks, and market projections—supported by detailed data and a visual graph. 1. Overview of Pharmaceutical Stocks Definition & Significance: Pharmaceutical stocks represent companies engaged in the research, development, manufacturing, and marketing of drugs and therapies. This sector is crucial for improving global health outcomes through innovative

When people talk about the next trillion-dollar tech giant, $Oracle(ORCL)$ isn’t usually the first name that comes to mind. Yet, this enterprise stalwart is quietly assembling the pieces for a major leap forward. With a current valuation of around $403 billion, Oracle’s aggressive expansion into AI and cloud computing could soon make it a heavyweight contender. Let’s break down why this database veteran may be one of the most underrated growth stories in tech today. AI Infrastructure: Oracle’s Not Here to Out-Amazon Amazon Many investors wrongly assume that Oracle is trying to go head-to-head with AWS or Azure in the cloud wars. That’s not the play here. Instead, Oracle is strategically positioning itself as the go-to provider for high-performance

On early Mon, 17 Mar 2025 morning (4am US time), US stock futures are looking grim again, coming off Friday’s mini-recovery rally. (see below) US market is going to start the week, marginally lower than last week’s closing. While there is no clear indication that US market will continue to trend lower thereafter. Neither could we foretell that its course may turnaround and rises instead, later in the day. It is a wait-and-see “game”. What is certain ? One of Wall Street preoccupations this week will be, US’s Fed FOMC meeting Mar 18-19. Traders will be dying to know: Central bank’s decision on interest rates. Fed chair Powell’s thoughts on the path forward. Hear him on his thoughts on overall health of US economy that many are certain has been wrecked by the Trump administration and preside

$Lucid Group Inc(LCID)$ Lucid, the electric vehicle company, has seen its shares drop by 28% so far in 2025. If you watched my video at the start of the year, I advised against buying Lucid stock in 2025. But now that it’s already down 28%, does that make it a good buying opportunity? I’ll answer that in this video by evaluating the company’s recent performance, its prospects with the Lucid Gravity SUV that just launched, its cash flow, and its valuation to see if it’s time to invest in Lucid stock. From a consumer standpoint, I’m a fan of Lucid. It’s my favorite electric vehicle because of its stunning designs. When I see a Lucid on the road, it looks beautiful—by far my favorite electric car in terms of aesthetics. However, as much as I admire t

$NVIDIA(NVDA)$ $Tradr 1.5X Short NVDA Daily ETF(NVDS)$ $Direxion Daily NVDA Bear 1X Shares(NVDD)$ 🚨🔥💥 $NVDA: Triple Top Showdown, Will It CRASH or SOAR? 💥🔥🚨 Hey, fearless traders! Nvidia is staging an epic battle on the charts, and we’ve got front row seats! The $NVDA chart is screaming with a classic “Triple Top” rejection between $122.74 and $123.70 (with a peak at $122.37), a beastly resistance that’s got bulls sweating and bears roaring! Is this the setup for a savage drop, or can the bulls stage a heroic breakout? Let’s dissect this like market ninjas! 🥋📈 📉 Key Battlegrounds to Watch Like a Hawk:    •   Red Fortress (Supply Zone

$ulta beauty(ULTA)$ Earning Overview Ulta reported $8.46 EPS, beating expectations by $1.31—a massive beat. Revenue also topped estimates by $10 million, though year-over-year revenue growth has slowed. Comparable sales increased 1.5%, and while the company posted a double beat for the quarter, its full-year guidance slightly missed expectations. ​Ulta Beauty reported its fourth-quarter fiscal 2024 earnings on March 13, 2025, delivering results that exceeded market expectations. The company's net sales for the quarter were $3.49 billion, a slight decrease of 1.9% from the previous year's $3.56 billion. This decline was primarily due to an extra week of sales in the prior year's quarter, which contributed approximately $181.9 million. When adjustin

$Walgreens Boots Alliance(WBA)$ Walgreens Announcement and Investor Lessons Walgreens announced today that it will go private in a deal worth around $10 billion with Sycamore Partners. I wanted to discuss some lessons investors can take away from this, as well as why I personally don't invest in turnaround stocks. This example really highlights why avoiding certain investment strategies can save you from making costly mistakes. My Investing Journey and the Rise of Dividend Growth Investing I first started writing about investing nearly 10 years ago, back in the third quarter of 2015. At that time, Seeking Alpha was a hotspot for dividend growth investors (and still is), but this was especially true before AI and other trends took over. Because bond

$Hims & Hers Health Inc.(HIMS)$ Hims & Hers, the rapidly growing telehealth company, has experienced an extraordinary surge over the past few months. In my previous articles on Hims, particularly The Messy Reality of Telehealth, I discussed the disconnect between the company's valuation and its intrinsic worth, arguing that Hims stock was significantly undervalued at the time. Around four months ago, Hims was trading at $23 per share. Fast forward to today, and the stock has not only surpassed my base case price target of $45 but also exceeded my bullish target of $62. However, in the past couple of weeks, Hims stock has pulled back sharply, dropping nearly 50% from its peak of $70 to approximately $33 per share. In this article, I'll anal

$Novo-Nordisk A/S(NVO)$ NVO's Shocking Decline In my previous analysis on NVO stock, I provided insights into its performance. Today, I decided to offer another update, especially now that the stock has dropped 42% over the past year. It’s absolutely shocking for a company like NVO—one of the best-performing stocks of all time, up 58,000% historically. Yet, it’s now plunging, down nearly 50% from its all-time high. Key Focus of This Update In this update, I'll discuss NVO's recent performance, why the stock is declining, and whether I believe it's presenting a generational buying opportunity at $76 per share—or if it remains overvalued and we should wait for a lower price. My View on Pharmaceutical Stocks Personally, I’m not a huge fan of holding p

$Trade Desk Inc.(TTD)$ Stock Performance and Recent Decline Since I first invested in The Trade Desk, its stock has risen over 10 times, but the journey has been anything but smooth. As you can see over the past three years, it’s been quite a roller coaster—actually, the stock is down over that period. If you zoom in more recently, you'll notice that year-to-date, the stock has lost more than 50% of its value. So, does this mean The Trade Desk is suddenly on the verge of going out of business, or what’s going on with the company that could cause such a sharp decline in value? Typically, a loss of this magnitude in such a short period raises some red flags. Let’s dive in and figure out what’s happening with The Trade Desk. My Experience with The Tra

$Medical Properties(MPW)$ MPW Stock Update: A Wild Ride MPW stock has been on an absolute tear—up 46% while the broader market is declining. Last year, when the market was rising, MPW was down 40-50%. It’s been a rollercoaster, so I’m doing an update to share my thoughts on whether the stock is approaching overvalued territory or if it’s still a solid opportunity. I’ll also break down the key factors driving this surge. I know some of you have commented about my stock picks, saying you lost money on MPW. As I’ve mentioned before, this stock moves inversely with the 10-year Treasury yield—it has a negative 80% correlation. When interest rates go down, MPW goes up. Why? Because MPW is a dividend stock, and as yields drop, its dividend becomes more at

$S&P 500(.SPX)$ $NASDAQ(.IXIC)$ The 1970s Inflation Crisis and Market Collapse In the 1970s, the U.S. experienced three major inflationary waves, with inflation soaring as high as 15%. Each wave triggered significant stock market declines, with U.S. equities falling by over 20% each time. Fast forward to today, and inflation is once again a growing concern. The recent surge in inflation, the highest since the 1970s, led to a 25% drop in stocks in 2022. Now, with the Trump administration's proposed policies, some economists warn that this could be the beginning of another prolonged inflationary cycle, much like the one seen in the 1970s. IMF Warnings on Inflationary Risks The International Monetary Fu

$Adobe(ADBE)$ The markets have opened with highly mixed results across various sectors. However, one standout movement is Adobe, which is down nearly 12%, aligning with the broader decline in the technology software industry. Looking at the past month, the market has been dominated by red, with many companies experiencing double-digit losses—Adobe included, which has dropped an additional 5%. Improved Market Sentiment On a more positive note, market sentiment is slightly improving. Just a few days ago, fear levels were extreme at 13, but they have now risen to 22. The hope is that this trend continues, moving away from extreme fear into a more stable range. Adobe's Earnings Report: A Closer Look Today, Adobe is in the spotlight following its lates

$GRANITESHARES 2X LONG BABA DAILY ETF(BABX)$ $Alibaba(BABA)$ $3X BABA(BAB3.UK)$🇨🇳🔥🌐⚒️ Alibaba’s Algorithmic Dominion Expands, $BABX as My Conduit into a Predictive Matrix ⚒️🌐 Tiger Traders, on 18 March 2025 (NZ time), I’ve anchored into $BABX, the 2x Long BABA ETF, at $34.91, now up 0.76%, as Alibaba ($BABA) commands $147.78, a 66% YTD titan outmuscling OKTA, TEM, SMCI, and PDD. This isn’t a transient blip, it’s a coded reconfiguration of market geometry, beckoning a trader’s precision scalpel. 📈 The Structural Lattice $BABA has obliterated 52 week highs, propelled by StockConnect’s record inflows and China’s consumption renaissance. Its new AI model, rivallin

As healthcare continues to evolve rapidly, pharmaceutical stocks are at the forefront of innovation in drug development and personalized medicine. In 2025, companies in this sector are leveraging breakthroughs in genomics, immunotherapy, and digital health to deliver cutting-edge treatments. This post explores the fundamentals of pharmaceutical stocks, key drivers behind their growth, diverse applications, investment opportunities and risks, and market projections—supported by detailed data and a visual graph. 1. Overview of Pharmaceutical Stocks Definition & Significance: Pharmaceutical stocks represent companies engaged in the research, development, manufacturing, and marketing of drugs and therapies. This sector is crucial for improving global health outcomes through innovative

The last economic report for the week dropped in on Fri, 14 Mar 2025. According to the University of Michigan’s latest consumer survey, Americans are getting more and more concerned about Trump's escalating and haphazard trade war. As a result, the US Consumer Sentiment fell to a more than 2-year low and long-term inflation expectations jumped by the most since 1993. (see below) Consumer sentiment fell -11% in March 2025, to a preliminary reading of 57.9, down from February’s 64.7 and reaching its lowest level since November 2022. That’s a really sharp retreat from December 2024’s, shortly after US presidential election, when sentiment rose to its highest level of “74” in months. Funnily enough, the disappointing report did not dampen US market sentiments on Friday when US stocks jumped in

Why Hims is on Solid Legal Ground to Continue Selling GLP-1s Even After the Shortage is Over Morgan Stanley analyst Craig Hettenbach just dropped some exciting news for investors in mail-order pharmaceuticals!   According to third-party data, downloads of the Hims & Hers apps skyrocketed 47% year-over-year in February—a massive surge in interest.  On Apple's App Store, Hims & Hers offers two distinct apps: Hims, focused on hair loss and sexual health, and Hers, catering to hair care and mental health. Morgan Stanley's research reveals that the Hers app dominated February's downloads, signaling a wave of new female customers.   What’s behind the spike? A certain high-profile sporting event likely played a role, with targeted ads driving attention to weight-l

As global economic uncertainty and shifting consumer behaviors persist, consumer staples stocks continue to offer stability and steady returns. These companies—providing essential products like food, beverages, and household goods—tend to perform well even during downturns, making them a cornerstone of defensive investing. In 2025, advancements in supply chain technology, sustainability initiatives, and digital transformation are reshaping the sector. This post explores the fundamentals of consumer staples stocks, key market drivers, diverse applications, investment opportunities and risks, and market projections—backed by detailed data and a visual graph. 1. Overview of Consumer Staples Stocks Definition & Significance: Consumer staples stocks represent companies that produce and

This week's market focus will be on the Federal Reserve's interest rate decision and the February retail sales data, which reflects economic strength. Looking back at last week's U.S. stock market, the $Dow Jones(.DJI)$ fell by over 1,000 points, while the $S&P 500(.SPX)$ and $NASDAQ(.IXIC)$ each declined by more than 2%. 1. The three major indices hit six-month lows. Compared to this year's peak, the $S&P 500(.SPX)$ has dropped by more than 10%, entering a correction zone.The market generally expects that the Fed will maintain the benchmark interest rate unchanged this time and is also focused on the economic f

$Wolfspeed Inc.(WOLF)$ Wolfspeed is another unfortunate casualty of the slow-growing electric vehicle (EV) industry. As a key supplier of silicon carbide chips critical for EV powertrains and charging infrastructure, Wolfspeed was banking on the growth of the EV sector to drive increased sales. However, the situation has gone in the opposite direction, and the company’s 12-month revenue is significantly lower than previous years. It is currently in the midst of a transition and attempting to recover, but the outcome remains uncertain. Earning Overview ​Wolfspeed Inc. (WOLF) reported its fiscal second-quarter earnings for 2025 on January 29, 2025. The company achieved revenues of $180.5 million, slightly surpassing Wall Street's consensus estimate

$S&P 500(.SPX)$ The U.S. Economy Takes Another Hit Investors Lose Confidence in Trump Global investors are losing confidence in Trump, despite his promises to restore America’s "Golden Age." His actions, however, suggest an economy in decline, with markets continuing to tumble. Meanwhile, his social media outbursts are becoming increasingly erratic. Escalating Trade Tensions Trump recently claimed that the U.S. lacks free trade and is being exploited by other nations. His solution? Doubling tariffs on Canada—just the beginning of escalating trade tensions. Over the coming weeks, the situation is expected to intensify. The administration is rolling out a 25% tariff on Mexico and Canada, along with a 20% tariff on China, marking the start of a d